Abstract
The chapter is divided into groups by different types of addictive substances with particular respect to specific features pertaining to the potential risks of the development of cognitive deficits associated with the use thereof. Considerably greater attention is paid to some of the substances, as the users of such substances and the consequences of using them are encountered more frequently in practice.
For example, this emphasis was applied for cannabis and MDMA ("ecstasy"), as these are substances that have become very popular among adolescents and young adults, and there are no signs of any major reversal of this tendency. Significant attention was also paid to the group of stimulants whose risk in terms of cognitive deficits is unfortunately often underestimated in practice, as opposed to the risk associated with opioid use, which, conversely, is overestimated.
A separate area of concem involves volatile substances whose signiťicant risks, including those to cognitive functions, are well known-the professional community has been pointing this issue out-but these facts are not adequately reflected in writings published in professional journals, nor in other messages. Finally, the concluding section of the chapter deals with assessment methods and recommended procedures for the identification and proposal of treatment and rehabilitation interventions aimed at addressing cognitive deficits caused by addictive substance use.